ES2280392T3 - Derivados de 1,4-diazepan-2,5-diona y su empleo como antagonistas del receptor de la nk-1. - Google Patents

Derivados de 1,4-diazepan-2,5-diona y su empleo como antagonistas del receptor de la nk-1. Download PDF

Info

Publication number
ES2280392T3
ES2280392T3 ES01960225T ES01960225T ES2280392T3 ES 2280392 T3 ES2280392 T3 ES 2280392T3 ES 01960225 T ES01960225 T ES 01960225T ES 01960225 T ES01960225 T ES 01960225T ES 2280392 T3 ES2280392 T3 ES 2280392T3
Authority
ES
Spain
Prior art keywords
benzyl
compound
formula
methyl
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01960225T
Other languages
English (en)
Spanish (es)
Inventor
Guido Galley
Annick Goergler
Thierry Godel
Reinhard Heck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2280392T3 publication Critical patent/ES2280392T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES01960225T 2000-05-25 2001-05-18 Derivados de 1,4-diazepan-2,5-diona y su empleo como antagonistas del receptor de la nk-1. Expired - Lifetime ES2280392T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111249 2000-05-25
EP00111249 2000-05-25

Publications (1)

Publication Number Publication Date
ES2280392T3 true ES2280392T3 (es) 2007-09-16

Family

ID=8168838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01960225T Expired - Lifetime ES2280392T3 (es) 2000-05-25 2001-05-18 Derivados de 1,4-diazepan-2,5-diona y su empleo como antagonistas del receptor de la nk-1.

Country Status (18)

Country Link
US (1) US6452001B2 (enExample)
EP (1) EP1296961B1 (enExample)
JP (1) JP4060596B2 (enExample)
KR (1) KR100526696B1 (enExample)
CN (1) CN1178923C (enExample)
AR (1) AR028607A1 (enExample)
AT (1) ATE353881T1 (enExample)
AU (2) AU2001281778B2 (enExample)
BR (1) BR0111062A (enExample)
CA (1) CA2409842C (enExample)
DE (1) DE60126614T2 (enExample)
DK (1) DK1296961T3 (enExample)
ES (1) ES2280392T3 (enExample)
MX (1) MXPA02011464A (enExample)
PE (1) PE20011266A1 (enExample)
PT (1) PT1296961E (enExample)
WO (1) WO2001090083A1 (enExample)
ZA (1) ZA200208940B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
DE602006016168D1 (de) * 2005-12-29 2010-09-23 Immupharma France Sa 1,3,5-triazepin-dionen zur Behandlung von Malaria
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
JP2009522236A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー マラリアまたはエイズの処置のためのアザ複素環化合物
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
KR101044833B1 (ko) * 2010-02-10 2011-06-28 (주)혜성나노텍 무차광 온실 보온커텐 종형 개폐장치
CN103951624B (zh) * 2010-08-26 2019-04-16 兴和株式会社 1,4-二氮杂环庚烷衍生物或其盐的制造方法
CA2839385C (en) 2011-06-24 2018-10-30 Construction Research & Technology Gmbh Cementitious composition and admixture
CN108358893A (zh) * 2018-02-10 2018-08-03 安徽唯诗杨信息科技有限公司 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022765A (en) 1975-01-06 1977-05-10 E. R. Squibb & Sons, Inc. Triazolo[4,3-d][1,4]benzodiazepine-6-ones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
DE60126614D1 (de) 2007-03-29
ZA200208940B (en) 2004-02-04
AR028607A1 (es) 2003-05-14
BR0111062A (pt) 2003-06-10
KR20030003759A (ko) 2003-01-10
JP2003534332A (ja) 2003-11-18
DE60126614T2 (de) 2007-11-22
CA2409842A1 (en) 2001-11-29
DK1296961T3 (da) 2007-06-04
EP1296961A1 (en) 2003-04-02
JP4060596B2 (ja) 2008-03-12
MXPA02011464A (es) 2003-04-25
US6452001B2 (en) 2002-09-17
ATE353881T1 (de) 2007-03-15
KR100526696B1 (ko) 2005-11-08
AU8177801A (en) 2001-12-03
PT1296961E (pt) 2007-05-31
CN1430611A (zh) 2003-07-16
EP1296961B1 (en) 2007-02-14
CA2409842C (en) 2008-07-29
WO2001090083A1 (en) 2001-11-29
CN1178923C (zh) 2004-12-08
US20020010174A1 (en) 2002-01-24
PE20011266A1 (es) 2001-12-14
AU2001281778B2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
ES2216297T3 (es) Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
CA2175502C (en) Cyclic amide derivatives
JP3243212B2 (ja) 四級塩基性アミドを含有する薬剤
JPH11147872A (ja) Ｃｃｒ−３受容体アンタゴニスト
JPH08504435A (ja) タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
CA2550735A1 (en) Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
SK286568B6 (sk) Inhibítory farnezyl proteín transferázy
SK30294A3 (en) Antagonists of 5-ht4 receptors
CN103228660A (zh) Kat ii 抑制剂
CN101119967A (zh) 1,5-二芳基吡咯衍生物、它们的制备与治疗用途
US6974870B2 (en) Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
JP2002517480A (ja) インテグリンインヒビターとしてのフェニルアラニン誘導体
BR112015004511B1 (pt) Derivados de pirazol carboxamida como moduladores de taar para uso no tratamento de diversas desordens, tais como depressão, diabetes e doença de parkinson
US6452001B2 (en) Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
AU2001281778A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists
US20100168099A1 (en) 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
ES2226493T3 (es) Oximas e hidrazonas sustituidas como antagonistas de neroquinina.
JPH04230358A (ja) α−メルカプトアルキルアミンの新規なＮ−置換誘導体、それらの製造法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物
JP5492189B2 (ja) Ｃｃｒ１０アンタゴニストである２−スルホニルアミノ−４−ヘテロアリールブチロアミド
JP2006117568A (ja) チオフェン環を有する新規アミド誘導体及びその医薬としての用途
ES2380270T3 (es) Derivados de espiropiperidina como antagonistas de NK3
AU2007283570A1 (en) 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
AU753582B2 (en) Substituted oximes as neurokinin antagonists
JP2007197428A (ja) 医薬組成物
ES2382415T3 (es) Derivados de piperidina como antagonistas de receptores de NK3